BL-1020 + BL 1020 High Dose
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia, Schizoaffective Disorder
Trial Timeline
Jun 1, 2007 → Dec 1, 2007
NCT ID
NCT00480571About BL-1020 + BL 1020 High Dose
BL-1020 + BL 1020 High Dose is a phase 2 stage product being developed by BioLineRx for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00480571. Target conditions include Schizophrenia, Schizoaffective Disorder.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00480571 | Phase 2 | Completed |
Competing Products
20 competing products in Schizophrenia